Updated:
Hippocrates Ventures
Hippocrates Ventures backs early-stage healthcare founders from New York, focusing on first-check investments in digital health and clinical care delivery.
Hippocrates Ventures
Hippocrates Ventures operates as an early-stage healthcare investment firm based in New York. Founded by emerging healthcare investors, the firm deploys capital into pre-seed and seed-stage startups building at the intersection of care delivery, digital health platforms, and provider enablement. The firm identifies founders solving operational bottlenecks in clinical workflows, patient access, and value-based care models. The firm's strategy centers on first-check investing—leading or co-leading seed rounds with initial checks sized for pre-revenue and early-traction healthcare companies. Portfolio construction blends digital health infrastructure bets with care-delivery innovation, spanning health-tech SaaS, AI-enabled diagnostics support, and novel care navigation models. Known positions include early-stage participants in digital health marketplaces and clinical workflow tools. The firm invests predominantly across the United States, with a concentration in East Coast and Midwest health systems innovation hubs. Hippocrates Ventures runs a compact team from New York. The firm maintains an operator-centric sourcing model, tapping founder networks within academic medical centers and health-tech accelerators. Recent activity includes participation in seed-stage syndicates backing AI-assisted clinical documentation and direct-primary-care enablement platforms. The firm does not operate adjacent philanthropic or real-asset vehicles. Structurally, Hippocrates Ventures stands apart through its single-stage concentration in a sector where many competitors scale into multi-stage platforms. The firm's governance and succession remain founder-led and flat, with investment decisions resting on a small partnership that evaluates clinical impact and reimbursement pathway risk before committing.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Hippocrates Ventures?
Investment decisions are led by the firm's founding partners, who evaluate healthcare startups through a combined lens of clinical viability, reimbursement alignment, and founder-market fit. The team operates with a flat structure where core partners share decision-making authority on seed-stage commitments. Specific named decision-makers beyond Aimee Runyon have not been publicly detailed.
How does Hippocrates Ventures source proprietary deal flow?
The firm relies on operator networks within academic medical centers, digital health accelerators, and clinician-founder communities. This sourcing model prioritizes referrals from practicing physicians and health system executives who encounter workflow pain points firsthand. The New York base provides proximity to major hospital networks and health-tech talent concentrations.
What investment stages does Hippocrates Ventures target?
Hippocrates Ventures concentrates on pre-seed and seed-stage healthcare companies, typically participating as a lead or co-lead in first institutional rounds. The firm focuses on pre-revenue and early-traction startups developing digital health platforms, clinical workflow tools, and care delivery models. Multi-stage or growth-equity positions are not part of the stated strategy.
Which sectors does Hippocrates Ventures explicitly avoid?
The firm does not invest in biotech therapeutics, medical devices requiring FDA PMA approval, or traditional healthcare services roll-ups. Its mandate is confined to capital-efficient digital health platforms and tech-enabled care delivery models. Biopharma and deep-tech hardware fall outside the investment scope.
What is Hippocrates Ventures' known posture on co-investments alongside external GPs?
Hippocrates Ventures regularly co-invests alongside other early-stage healthcare funds and angel syndicates, particularly in rounds where sector-specialist GPs can provide complementary clinical diligence. The firm does not publicly operate a formal co-investor club, but has participated in syndicated seed rounds alongside health-tech accelerators and other specialist seed funds in New York and Boston. (public record)
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: